Phase I/II Study of the Anti-Programmed Death Ligand-1 Antibody MEDI4736 in Combination With Olaparib and/or Cediranib for Advanced Solid Tumors and Advanced or Recurrent Ovarian, Triple Negative Breast, Lung, Prostate and Colorectal Cancers

Clinical Trial ID NCT02484404

PubWeight™ 6.48‹?›

🔗 Visit the ClinicalTrials.gov page for NCT02484404

Top papers

Rank Title Journal Year PubWeight™‹?›
1 PD-1/PD-L1 blockade in cancer treatment: perspectives and issues. Int J Clin Oncol 2016 0.95
2 Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer? Int J Mol Sci 2016 0.90
3 The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract 2016 0.81
4 New treatment option for ovarian cancer: PARP inhibitors. Gynecol Oncol Res Pract 2016 0.80
5 Emerging therapeutic targets in metastatic progression: A focus on breast cancer. Pharmacol Ther 2016 0.79
6 Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment. J Transl Med 2016 0.79
7 Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. Ther Adv Med Oncol 2016 0.77
8 Future perspectives in cancer immunotherapy. Ann Transl Med 2016 0.77
Next 100